See more : Arian Resources Corp. (GNHRF) Income Statement Analysis – Financial Results
Complete financial analysis of TRxADE HEALTH, Inc. (MEDS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of TRxADE HEALTH, Inc., a leading company in the Medical – Pharmaceuticals industry within the Healthcare sector.
- Major Precious Metals Corp. (SIZYF) Income Statement Analysis – Financial Results
- Galiano Gold Inc. (GAU.TO) Income Statement Analysis – Financial Results
- Jardine Matheson Holdings Limited (JMHLY) Income Statement Analysis – Financial Results
- Daiichi Co.,Ltd. (7643.T) Income Statement Analysis – Financial Results
- Tengjun Biotechnology Corp. (TJBH) Income Statement Analysis – Financial Results
TRxADE HEALTH, Inc. (MEDS)
About TRxADE HEALTH, Inc.
TRxADE HEALTH, Inc. operates as a health services IT company in the United States. The company focuses on digitalizing the retail pharmacy experience by optimizing drug procurement, prescription journey, and patient engagement. It operates the TRxADE drug procurement marketplace, which fosters price transparency and serves approximately 11,800 members; and offers patient centric telehealth services under the Bonum Health brand name. The company was formerly known as Trxade Group, Inc. and changed its name to TRxADE HEALTH, Inc. in June 2021. TRxADE HEALTH, Inc. is based in Land O' Lakes, Florida.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2008 | 2007 | 2006 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 8.27M | 11.45M | 9.89M | 17.12M | 7.44M | 3.83M | 2.93M | 2.48M | 4.99M | 1.50M | 955.88K | 806.05K | 0.00 | 0.00 | 0.00 |
Cost of Revenue | 5.67M | 6.00M | 5.14M | 11.42M | 2.57M | 449.05K | 0.00 | 16.36K | 1.93M | 440.05K | 944.07K | 689.81K | 0.00 | 0.00 | 0.00 |
Gross Profit | 2.60M | 5.45M | 4.75M | 5.71M | 4.87M | 3.38M | 2.93M | 2.47M | 3.06M | 1.06M | 11.81K | 116.24K | 0.00 | 0.00 | 0.00 |
Gross Profit Ratio | 31.41% | 47.62% | 47.99% | 33.33% | 65.50% | 88.28% | 100.00% | 99.34% | 61.38% | 70.59% | 1.24% | 14.42% | 0.00% | 0.00% | 0.00% |
Research & Development | 1.38M | 1.16M | 1.37M | 662.73K | 647.14K | 949.95K | 375.17K | 286.76K | 319.44K | 319.44K | 611.71K | 198.41K | 0.00 | 0.00 | 3.57K |
General & Administrative | 8.48M | 7.05M | 8.81M | 7.49M | 4.38M | 2.35M | 2.27M | 3.30M | 3.70M | 2.11M | 2.10M | 266.95K | 28.50M | 0.00 | 5.16K |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 147.63K | 355.12K | 374.62K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 8.48M | 7.05M | 8.81M | 7.49M | 4.38M | 2.35M | 2.27M | 3.45M | 4.05M | 2.49M | 2.10M | 266.95K | 28.50M | 24.77K | 5.16K |
Other Expenses | 14.54K | 1.60M | -1.23M | 3.25M | 72.08K | 161.64K | 67.50K | 131.27K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.42K | 0.00 |
Operating Expenses | 9.86M | 8.21M | 8.81M | 7.49M | 4.38M | 3.30M | 2.27M | 3.45M | 4.05M | 2.49M | 2.10M | 266.95K | 28.50M | 28.19K | 8.73K |
Cost & Expenses | 15.54M | 14.20M | 13.96M | 18.90M | 6.94M | 3.75M | 2.27M | 3.47M | 5.98M | 2.93M | 3.04M | 956.76K | 28.50M | 28.19K | 8.73K |
Interest Income | 4.20K | 20.99K | 23.59K | 29.39K | 53.23K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 1.20M | 336.21K | 23.59K | 29.39K | 53.23K | 57.54K | 157.06K | 151.50K | 130.14K | 4.15K | 7.28K | 0.00 | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 1.05M | 194.70K | 138.91K | 102.52K | 94.73K | 87.62K | -395.10K | 8.67K | 3.80K | 4.80K | 3.99K | 2.63K | 0.00 | 0.00 | 0.00 |
EBITDA | -13.72M | -1.85M | -5.15M | -2.51M | 660.55K | 96.65K | 288.98K | -984.03K | -133.27K | -2.00M | -2.08M | -148.09K | -28.50M | -28.19K | -8.73K |
EBITDA Ratio | -74.89% | -22.18% | -52.11% | -9.80% | 8.88% | 6.36% | 24.92% | -39.65% | -19.70% | -95.35% | -217.60% | -18.37% | 0.00% | 0.00% | 0.00% |
Operating Income | -7.26M | -2.76M | -5.29M | -1.78M | 565.82K | -87.62K | 395.10K | -984.03K | -987.05K | -1.43M | -2.08M | -150.71K | -28.50M | -28.19K | -8.73K |
Operating Income Ratio | -87.80% | -24.08% | -53.51% | -10.40% | 7.61% | -2.29% | 13.48% | -39.65% | -19.77% | -95.67% | -218.02% | -18.70% | 0.00% | 0.00% | 0.00% |
Total Other Income/Expenses | -6.46M | -362.72K | -23.59K | -29.39K | -778.17K | 96.65K | -106.11K | -165.83K | -119.51K | -580.57K | -7.28K | 0.00 | 28.47M | 0.00 | 0.00 |
Income Before Tax | -13.72M | -3.91M | -5.32M | -2.54M | -284.43K | 9.04K | 288.98K | -1.17M | -1.12M | -2.01M | -2.09M | -150.71K | -28.50K | 0.00 | 0.00 |
Income Before Tax Ratio | -165.86% | -34.15% | -53.75% | -14.81% | -3.82% | 0.24% | 9.86% | -47.27% | -22.38% | -134.47% | -218.78% | -18.70% | 0.00% | 0.00% | 0.00% |
Income Tax Expense | 5.34M | 400.34K | -1.20M | 29.39K | 125.30K | -154.20K | -50.94K | 1.62M | 130.14K | 576.42K | 7.28K | 0.00 | 28.50M | 28.19K | 8.73K |
Net Income | -17.84M | -4.31M | -4.11M | -2.57M | -409.73K | 9.04K | 288.98K | -2.76M | -1.12M | -2.01M | -2.09M | -150.71K | -28.50M | -28.19K | -8.73K |
Net Income Ratio | -215.70% | -37.65% | -41.59% | -14.98% | -5.51% | 0.24% | 9.86% | -111.21% | -22.38% | -134.47% | -218.78% | -18.70% | 0.00% | 0.00% | 0.00% |
EPS | -23.35 | -7.63 | -7.58 | -4.99 | -1.04 | 0.02 | 0.81 | -7.89 | -3.20 | -6.30 | -13.50 | -0.97 | -273.59 | -0.27 | -0.11 |
EPS Diluted | -7.49 | -7.63 | -7.58 | -4.99 | -1.04 | 0.02 | 0.81 | -7.87 | -3.20 | -6.07 | -13.35 | -0.97 | -269.45 | -0.27 | -0.11 |
Weighted Avg Shares Out | 764.06K | 564.86K | 542.45K | 513.71K | 395.27K | 388.43K | 355.06K | 349.64K | 349.64K | 319.37K | 154.91K | 154.91K | 104.16K | 105.76K | 81.20K |
Weighted Avg Shares Out (Dil) | 2.38M | 564.86K | 542.45K | 513.71K | 395.27K | 388.43K | 378.74K | 350.50K | 349.64K | 331.46K | 156.69K | 154.91K | 105.76K | 105.76K | 81.20K |
TRxADE HEALTH, INC to Present at LD Micro Invitational XI
TRxADE Group Announces Strategic Telehealth Partnership with Brookshire Grocery Company
TRxADE Group Announces Milestone Group Purchasing Agreement with QualityCare Pharmacies
Trxade Group, Inc. (MEDS) CEO Suren Ajjarapu on Q1 2021 Results - Earnings Call Transcript
TRxADE Group Reports Record First Quarter 2021 Financial Results
Trxade Group to Report First Quarter 2021 Financial Results on Monday, April 26th at 5:00 p.m. Eastern Time
TRxADE Group to Present at Planet MicroCap Showcase
Trxade Group, Inc.'s (MEDS) CEO Suren Ajjarapu on Q4 2020 Results - Earnings Call Transcript
TRxADE Group Reports Annual Revenue Growth of 130% and Year End 2020 Financial Results
Trxade Group to Report Fourth Quarter and Full Year 2020 Results on Monday, March 29th at 5:00 p.m. Eastern Time
Source: https://incomestatements.info
Category: Stock Reports